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Purpose: Standard chemoradiation therapy for stage III non-small cell lung cancer (NSCLCa)
results in suboptimal outcomes with a high rate of local failure and poor overall survival.
We hypothesize that dose escalation using stereotactic body radiotherapy (SBRT) boost
could improve upon these results. We present here a study evaluating the dosimetric
feasibility of such an approach. Methods: Anonymized CT data sets from ﬁve randomly
selected patients with stage III NSCLCa undergoing deﬁnitive chemoradiation therapy in
our department with disease volumes appropriate for SBRT boost were selected. Three-
dimensional conformal radiation therapy (3D-CRT) plans to 50.4 Gy in 28 fractions were
generated follow by SBRT plans to two dose levels, 16 Gy in two fractions and 28 Gy in
two fractions. SBRT plans and total composite (3D-CRT and SBRT) were optimized and
evaluated for target coverage and dose to critical structures; lung, esophagus, cord, and
heart. Results: All ﬁve plans met predetermined target coverage and normal tissue dose
constraints. PTV V95 was equal to or greater than 95% in all cases. The cumulative lung
V20 and V5 of the combined 3D-CRT and SBRT plans were less than or equal to 30 and
55%, respectively. The 5 cc esophageal dose was less than 12 Gy for all low and high
dose SBRT plans. The cumulative dose to the esophagus was also acceptable with less
than 10% of the esophagus receiving doses in excess of 50 Gy.The cumulative spinal cord
dose was less than 33 Gy and heart V25 was less than 5%. Conclusion:The combination
of chemoradiation to 50.4 Gy followed by SBRT boost to gross disease at the primary
tumor and involved regional lymph nodes is feasible with respect to normal tissue dose
constraints in this dosimetric pilot study. A phase I/II trial to evaluate the clinical safety and
efﬁcacy of this approach is being undertaken.
Keywords: NSCLCa, SBRT, SAbR
INTRODUCTION
Lung cancer remains the leading cause of death for both men
and women in the US (Siegel et al., 2012). Although the results
of treatment for early stage non-small cell lung cancer (NSCLCa)
are encouraging, as many as 40% of patients present with stage
III disease (Chang et al., 2008). The standard treatment approach
for these patients is concurrent chemoradiation therapy with or
without surgery. However, overall survival with this approach is
expected to be only 15–35% at 5 years (Edge et al., 2010). Pat-
terns of failure show that both local and systemic relapse are
common. Local failure rate of 35–50% is expected with radia-
tion therapy using standard fractionation (1.8–2 Gy/fx) and doses
(60–70 Gy; Curran et al., 2011). In an attempt to improve upon
local control and outcomes, radiation dose escalation has been
investigated (Hayman et al., 2001; Narayan et al., 2004; Bradley
et al., 2005, 2010; Kong et al., 2005; Partridge et al., 2011). Stereo-
tactic body radiation therapy (SBRT) is a highly precise and
conformal method of delivering high doses of radiation ther-
apy. SBRT has shown impressive local control rates of 85–95%
in early stage lung cancer (Onishi et al., 2004, 2007; Nagata
et al., 2005; Nguyen et al., 2008; Baumann et al., 2009; Fakiris
et al., 2009; Timmerman et al., 2010). Such improvement in local
control has been correlated to the increased biologic equiva-
lent dose (BED) achieved with the radiation dose schema of
SBRT. In this study, we evaluated the dosimetric feasibility of
using SBRT as a boost to gross disease (primary lung tumor and
bulkymediastinal lymphadenopathy) following standard fraction-
ated three-dimensional conformal radiation therapy (3D-CRT) to
50.4 Gy.
METHODS
Anonymized CT data sets from ﬁve randomly selected patients
with stage IIINSCLCaundergoing deﬁnitive chemoradiation ther-
apy in our department were selected. Selected patients had to have
gross disease volumes amenable to SBRT boost. This was deﬁned
as primary tumor volume of less than or equal to 120 cc and
hilar/mediastinal disease involving one to two nodal stations with
volume less than or equal to 60 cc.
3D-CRT PLANS
Patients underwent CT simulation in the supine position with
arms up using an arm shuttle and alpha cradle for immobilization.
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Standard CT-based 3D-CRT treatment plans using a three to ﬁve
coplanar beam arrangement were generated to target the primary
tumor and nodal GTV as deﬁned by diagnostic PET and CT scans.
Amargin of 2 cmwas placed around all gross disease to account for
subclinical disease, set up error, and respiratory motion. Elective
nodal irradiation was not performed. Dose calculation were per-
formed using Pinnacle version 8.0m (Philips,Madison,WI,USA).
Heterogeneity correctionswere employed to correct for differences
in tissue density; the collapsed cone convolution (CCC) method
was used for dose calculation. A dose of 50.4 Gy in 1.8 Gy/fx was
prescribed. Isodose plans and dose volume histograms (DVHs)
were generated.
SBRT PLANS
Target volumes for SBRT boost consisted of gross tumor only
(GTV) with the standard PTV margin. Typically, patients under-
going SBRT in our department are simulated with appropriate
immobilization using the BlueBAG BodyFIX system (Elekta,
Stockholm, Sweden) and abdominal compression to reduce res-
piratory excursion. During simulation, respiratory gated image
acquisition is performed to determine target tumor motion in
order to generate a patient-speciﬁc ITV. Because patients were
simulated for 3D-CRT treatment without SBRT appropriate
immobilization and a respiratory dampening device, an accurate
SBRT ITV was not available for these patients. A margin expan-
sion of 1 cm in the superior and inferior directions and 0.5 cm
in the radial directions was, therefore, used. This margin corre-
sponds well to the typical margin expansion using for ITV and
PTV in our SBRT patient population as well as what is reported
in the literature (Fakiris et al., 2009). Dose calculation were per-
formed using Eclipse version 8.6 (Varian, Las Vegas, NV, USA).
Heterogeneity correction was used to correct for differences in tis-
sue density and the anisotropic analytical algorithm (AAA) was
employed for dose calculation. The primary lung tumor and the
hilar/mediastinal nodal disease were planned separately. Intensity
modulated radiation therapy (IMRT)was used employing an 8–14
non-coplanar beam arrangement. A composite of the two SBRT
plans was generated to evaluate for any signiﬁcant dose overlap
and to calculate the volume of low dose spillage. Two prescription
doses were evaluated: 16 Gy in two fractions and 28 Gy in two
fractions. These doses were selected based on a planned dose esca-
lation study with 16 Gy representing the starting dose and 28 Gy
representing the maximum target dose. Plans were normalized
such that 95% of the PTV was covered by 95% of the prescription
dose.
COMPOSITE PLANS
Composite plans between the 50.4 Gy 3D-CRT plan and SBRT
boost plan were generated for the ﬁve patients using the fusion
algorithm of Velocity version 2.5 (Atlanta, GA, USA). Composite
DVHs and isodose plans were generated. Plans were optimized to
meet dose constraints detailed in Tables 1 and 2. These dose con-
straints were selected based on commonly used and known dose
volume constraints for these organs based on conventional frac-
tionated and SBRT treatments. Cumulative dose limits between
the 3D-CRT and SBRT plans were based on BED conversion to
take into account differences in biological effect of varying dose
Table 1 | Stereotactic body radiotherapy boost dose constraints.
Organ Volume Dose Endpoint
(>/Grade 3)
Spinal cord Max point dose 9 Gy (4.5 Gy × 2) Myelitis
Lung 10% 7 Gy (3.5 Gy × 2) Pneumonitis
Esophagus <5 cc 12 Gy (6 Gy × 2) Stenosis/ﬁstula
Heart <15 cc 8 Gy (4 Gy × 2) Pericarditis
Great vessels <10 cc 24 Gy (12 Gy × 2) Aneurysm
Brachial plexus Max point dose 8 Gy (4 Gy × 2) Neuropathy
Rib <1 cc 16 Gy (8 Gy × 2) Pain or fracture
Skin <10 cc 16 Gy (8 Gy × 2) Ulceration
Stomach <10 cc 8 Gy (4 Gy × 2) Ulceration/ﬁstula
Table 2 | Cumulative dose constraints (EBRT and SBRT boost).
Organ Volume EQD2* Endpoint
(>/Grade 3)
Spinal cord Max point dose 45 Gy Myelitis
Lung <35% 20 Gy Pneumonitis
Lung <65% 5 Gy Pneumonitis
Esophagus 10 cm 60 Gy Stenosis/ﬁstula
Heart 25% 40 Gy Pericarditis
Brachial plexus Max point dose 66 Gy Neuropathy
*With α/β of 3 used for late normal tissue effects except for spinal cord and
brachial plexus were an α/β of 2 is used.
per fraction. BED and equivalent dose in 2 Gy fractions (EQD2)
calculation were based on the following equations.
BED = n × d × [1 + d/(α/β)] and
EQD2 = n × d × (d + α/β)/(2 + α/β)
An α/β of 10, 3, and 2 were used for tumor control, late tis-
sue affects, and late affects on spinal cord and neural structures,
respectively.
RESULTS
All ﬁve plansmet predetermined target coverage and normal tissue
dose constraints as deﬁned in Tables 1 and 2. PTV V95 was equal
to or greater than 95% in all cases. For the ﬁve cases studied,
the cumulative lung V20 of the combined 3D-CRT and SBRT
plans were 17, 30, 28, 33, 19 and 18, 30, 29, 34, 20% for low
dose and high dose SBRT, respectively. The cumulative lung V5
was similarly within acceptable limits, less than 55% for all plans.
The 5 cc esophageal dose was less than 12 Gy for all low and
high dose SBRT plans. The cumulative dose to the esophagus was
also low with less than 18% of the esophagus receiving doses in
excess of 50 Gy. In addition, heart and spinal cord doses were low.
Table 3 shows target and normal tissue doses for 3D-CRT plans,
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low dose SBRT and high dose SBRT plans, and composite plans.
The isodose distribution and DVH for each high dose SBRT boost
plan is depicted in Figure 1.
DISCUSSION
The results of deﬁnitive treatment for stage III NSCLCa are disap-
pointing with an expected 5 year survival of only 15–35% (Edge
et al., 2010). RTOG 9410 help establish concurrent chemora-
diation as the current standard treatment approach for these
patients (Curran et al., 2011). Patterns of failure from this study
have been reported and show that local-regional control with
cisplatin-based chemotherapy and concurrent radiation therapy
to 63 Gy in standard fractionation was only 65%. Furthermore,
25% of patients experience in-ﬁeld local failure only without
distant metastasis (Curran et al., 2011). The addition of surgery
to improve upon suboptimal local control was evaluated in
INT/RTOG 0139 (Albain et al., 2009). This trial showed improved
5 year progression-free survival from 11 to 22%, but overall sur-
vival was not improved. The lack of overall survival beneﬁt has
been attributed to early treatment related morbidity and mortal-
ity of the tri-modality arm particularly in patients who required
pneumonectomy. Many high volume and academic centers still
favor a tri-modality approach for select patients based on evi-
dence that the morbidity and mortality rates at these centers is
low with this approach (Allen et al., 2008). Nonetheless, many
patients are not ideal candidates for surgery due to concurrent
cardiac and/or pulmonary disease or due to the requirement for
pneumonectomy. Attempts to improve upon local disease con-
trol with radiation dose escalation have thus been undertaken.
This approach is grounded soundly in the fundamental princi-
ples of radiation biology. The higher the radiation dose, the larger
the fractional cell kill, and hence the greater the probability of
disease control. Kong et al. (2005) reported on the results of a
dose escalation trial which showed improved overall survival with
high radiation doses. At 5 years, overall survival was 4, 22, and
28% for patients receiving 63–69, 74–84, and 92–103 Gy, respec-
tively. Hayman et al. (2001) reported on dose escalation from 63
to 102.9 Gy with patients stratiﬁed based on treatment volumes.
Reported 3 year survival was 18%. RTOG 9311 showed feasibil-
ity of dose escalation to 83.8 Gy (Bradley et al., 2005). However,
with concurrent chemotherapy, amaximum tolerated dose of only
74 Gy could be achieved in RTOG 0117 (Bradley et al., 2010). Par-
tridge et al. (2011) performed a systematic review and modeling
analysis of published trials of dose escalation. They found a clear
dose–response relationship for improved disease-free survival.
Interestingly, the best outcomes were seen in hypofractionated
regimens.
RTOG 0617/CALGB 30609, a phase III randomized trial, was
designed to evaluate the efﬁcacy of dose escalation using concur-
rent chemoradiation for stage III NSCLCa (Bradley et al., 2011).
This trial consists of a 2 by 2 factorial design comparing 60
vs. 74 Gy with and without cetuximab. This trial unexpectedly
was closed early for futility after enrolling 450 patients. No dif-
ference in the primary endpoint of overall survival was seen
between the high and low dose arms. Several explanations can
be postulated for why this study failed to show a beneﬁt from
dose escalation. First, failure to control systemic disease may be
overshadowing any beneﬁt from improvements in local disease
control. Second, toxicity from dose escalation using conventional
3D-CRT may limit any beneﬁts gained. Third, 74 Gy is not a
high enough dose to result in a high rate of local disease con-
trol. And lastly, accelerated tumor repopulation that typically
begins after 4 weeks of treatment may be mitigating any tumor
cell kill gained from dose escalation using a protracted standard
fractionated regime.
The rationale to use SBRT boost as a method of dose escala-
tion addresses the later three postulates. The conformal nature of
an SBRT approach limits the amount of normal tissues receiving
radiation thereby allowing the potential for safer radiation dose
escalation. By delivering the boost in just two fractions, the detri-
mental effect of accelerated tumor repopulation is eliminated. And
ﬁnally, the dose of radiation can be signiﬁcantly elevated using an
SBRT approach. Although the optimal dose which results in high
likelihood of tumor control is not known for locally advanced
NSCLCa, one can extrapolate from the dose–response data gained
from early stage NSCLCa. Onishi et al. (2004) reported on the cor-
relation between the BED and local tumor control using several
SBRT dose and fractionation regime. They showed that at a BED
of greater than 100 Gy results in a 92% likelihood of local control
compared to 74% for BED less than 100 Gy. This resulted in a
statistically signiﬁcant improvement in 3 year overall survival of
88 vs. 69%, respectively.
In this study, we evaluate the dosimetric feasibility of chemora-
diation therapy using standard fractionation to 50.4 Gy to control
microscopic disease and systemic disease followed by an SBRT
boost to gross tumor. We evaluated two SBRT dose levels, 16 and
28 Gy in two fractions. This study shows that at both the low and
high dose levels, lung, heart, esophagus, and spinal cord dose can
be kept low and within reasonable accepted dose constraints. The
lung V20 and V5 for our cases was less than 30 and 55%, respec-
tively. These are below the doses at which a high risk pulmonary
toxicity is expected. Equally, the doses to other organs are within
acceptable limits (Timmerman, 2008; Marks et al., 2010).
This study has potential limitations. The sample size is small.
Although a variety of disease locations and distributions is repre-
sented by the evaluated patients (Figure 1). Not all possible disease
distributions are represented. Thus, some patients who meet the
inclusion criteria deﬁned in Section “Methods” may not be able
to meet the dose constraints set forth in this study. Furthermore,
the dose constraints selected are based on commonly accepted
dose constraints used for SBRT and conventional fractionation.
Some of these dose constraints were established empirically or
were based on conversions using the linear-quadratic model. This
model although useful has limitations especially when using large
dose per fraction. Thus, the dose constraints used in this study
may or may not be optimal constraints. Nonetheless, the present
study does support that at least some patients with stage III lung
cancer can be treated with this approach and achieve reasonable
dosimetric constraints to critical organs, and thus supports further
clinical evaluation of this approach.
We therefore are planning a phase I dose escalation study to
evaluate the clinical feasibility and any potential dose limiting tox-
icity of SBRT boost for stage III lung cancer. A starting dose of
16 Gy in two fractions will be used. The dose will then be increased
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FIGURE 1 | Orthogonal isodose distribution and DVH of SBRT boost plan to 28 Gy in two fractions.Three separate cases are depicted in (A–C).
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Table 4 | Biological equivalent dose (BED) and equivalent dose in 2 Gy
per fraction (EQD2) for tumor control at each dose level.
Levels Dose BED10 Cumulative*
BED10
EQD2 Cumulative§
EQD2
1 16 Gy (8 Gy × 2) 28.8 88.3 24 73.6
2 20 Gy (10 Gy × 2) 40 99.5 33.3 82.9
3 24 Gy (12 Gy × 2) 52.8 112.3 44 93.6
4 28 Gy (14 Gy × 2) 67.2 126.7 56 105.6
∗Combine with 3D-CRT of 50.4 Gy (BED10 59.5).
§Combine with 50.4 Gy 3D-CRT (EQD2 49.6).
by 2 Gy per fraction increments until a maximum dose of 28 Gy
in two fractions or dose limiting toxicity is reached. Table 4
shows the relative BED10 of each dose level. The initial dose level
is roughly equivalent to the BED10 of a standard conventional
fractionation treatment to 70 Gy. The dose escalation goal is to
reach a BED10 of greater than 100 Gy. The maximum dose level
was selected to be at a cumulative BED10 of less than 151 Gy,
since toxicity for centrally located tumors has been reported at
these doses (Timmerman et al., 2006). The maximum tolerated
dose will then be evaluated for efﬁcacy in a follow-up phase II
trial.
CONCLUSION
The combination of chemoradiation to 50.4 Gy followed by
SBRT boost to gross disease at the primary tumor and involved
regional lymph nodes is feasible with respect to normal tissue
dose constraints in this dosimetric pilot study. A phase I/II trial to
evaluate the clinical safety and efﬁcacy of this approach is being
undertaken.
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